New role of signal peptide peptidase to liberate C-terminal peptides for MHC class i presentation

Journal of Immunology

Volumn 191, Issue 8, 2013, Pages 4020-4028

  Oliveira, Cláudia C ^a,b   Querido, Bianca ^a   Sluijter, Marjolein ^a   De Groot, Anne F ^a   Van Der Zee, Reno ^a   Rabelink, Martijn J W E ^a   Hoeben, Rob C ^a   Ossendorp, Ferry ^a   Van Der Burg, Sjoerd H ^a   Van Hall, Thorbald ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDASE; PROTEASOME; PROTEIN TAP; PROTEIN TRH4; SIGNAL PEPTIDE PEPTIDASE; SPHINGOSINE ACYLTRANSFERASE; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MHC I GENE; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; RESIDUE ANALYSIS; SITE DIRECTED MUTAGENESIS; TAP1 GENE; TAP2 GENE; TRH4 GENE;

ANIMALS; ANTIGEN PRESENTATION; ASPARTIC ACID ENDOPEPTIDASES; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; HEK293 CELLS; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MEMBRANE PROTEINS; MICE; MUTATION; OXIDOREDUCTASES; PEPTIDES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84885445749     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301496     Document Type: Article

References (52)

1. Cresswell, P., A. L. Ackerman, A. Giodini, D. R. Peaper, and P. A. Wearsch. 2005. Mechanisms of MHC class I-restricted antigen processing and crosspresentation. Immunol. Rev. 207: 145-157.
2. Rock, K. L., D. J. Farfán-Arribas, and L. Shen. 2010. Proteases in MHC class I presentation and cross-presentation. J. Immunol. 184: 9-15.
3. Vyas, J. M., A. G. Van der Veen, and H. L. Ploegh. 2008. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8: 607-618.
4. Kessler, J. H., S. Khan, U. Seifert, S. Le Gall, K. M. Chow, A. Paschen, S. A. Bres-Vloemans, A. de Ru, N. van Montfoort, K. L. Franken, et al. 2011. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat. Immunol. 12: 45-53.
5. Seifert, U., C. Marañón, A. Shmueli, J. F. Desoutter, L. Wesoloski, K. Janek, P. Henklein, S. Diescher, M. Andrieu, H. de la Salle, et al. 2003. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4: 375-379.
6. Aldrich, C. J., H. G. Ljunggren, L. Van Kaer, P. G. Ashton-Rickardt, S. Tonegawa, and J. Forman. 1994. Positive selection of self-And alloreactive CD8+ T cells in Tap-1 mutant mice. Proc. Natl. Acad. Sci. USA 91: 6525-6528.
7. Sandberg, J. K., B. J. Chambers, L. Van Kaer, K. Kärre, and H. G. Ljunggren. 1996. TAP1-deficient mice select a CD8+ T cell repertoire that displays both diversity and peptide specificity. Eur. J. Immunol. 26: 288-293.
8. Van Kaer, L., P. G. Ashton-Rickardt, H. L. Ploegh, and S. Tonegawa. 1992. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 71: 1205-1214.
9. Cerundolo, V., and H. de la Salle. 2006. Description of HLA class I-And CD8-deficient patients: Insights into the function of cytotoxic T lymphocytes and NK cells in host defense. Semin. Immunol. 18: 330-336.
10. Zimmer, J., E. Andrès, L. Donato, D. Hanau, F. Hentges, and H. de la Salle. 2005. Clinical and immunological aspects of HLA class I deficiency. QJM 98: 719-727.
11. de la Salle, H., E. Houssaint, M. A. Peyrat, D. Arnold, J. Salamero, D. Pinczon, S. Stevanovic, H. Bausinger, D. Fricker, E. Gomard, et al. 1997. Human peptide transporter deficiency: importance of HLA-B in the presentation of TAPindependent EBV antigens. J. Immunol. 158: 4555-4563.
12. Lautscham, G., T. Haigh, S. Mayrhofer, G. Taylor, D. Croom-Carter, A. Leese, S. Gadola, V. Cerundolo, A. Rickinson, and N. Blake. 2003. Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2. J. Virol. 77: 2757-2761.
13. Chambers, B., P. Grufman, V. Fredriksson, K. Andersson, M. Roseboom, S. Laban, M. Camps, E. Z. Wolpert, E. J. Wiertz, R. Offringa, et al. 2007. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Cancer Res. 67: 8450-8455.
14. Oliveira, C. C., P. A. van Veelen, B. Querido, A. de Ru, M. Sluijter, S. Laban, J. W. Drijfhout, S. H. van der Burg, R. Offringa, and T. van Hall. 2010. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigenprocessing defects. [Published erratum appears in 2010 J. Exp. Med. 207: 671.] J. Exp. Med. 207: 207-221.
15. Seidel, U. J., C. C. Oliveira, M. H. Lampen, and Tv. Hall. 2012. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens. Cancer Immunol. Immunother. 61: 119-125.
16. van Hall, T., S. Laban, D. Koppers-Lalic, J. Koch, C. Precup, P. Asmawidjaja, R. Offringa, and E. J. Wiertz. 2007. The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1. J. Immunol. 178: 657-662.
17. van Hall, T., E. Z. Wolpert, P. van Veelen, S. Laban, M. van der Veer, M. Roseboom, S. Bres, P. Grufman, A. de Ru, H. Meiring, et al. 2006. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 12: 417-424.
18. Lampen, M. H., C. Hassan, M. Sluijter, A. Geluk, K. Dijkman, J. M. Tjon, A. H. de Ru, S. H. van der Burg, P. A. van Veelen, and T. van Hall. 2013. Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol. Immunol. 53: 126-131.
19. Weinzierl, A. O., D. Rudolf, N. Hillen, S. Tenzer, P. van Endert, H. Schild, H. G. Rammensee, and S. Stevanović. 2008. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur. J. Immunol. 38: 1503-1510.
20. Oliveira, C. C., and T. van Hall. 2013. Importance of TAP-independent processing pathways. Mol. Immunol. 55: 113-116.
21. Del Val, M., S. Iborra, M. Ramos, and S. Lázaro. 2011. Generation of MHC class I ligands in the secretory and vesicular pathways. Cell. Mol. Life Sci. 68: 1543-1552.
22. Gil-Torregrosa, B. C., A. Raúl Castaño, and M. Del Val. 1998. Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J. Exp. Med. 188: 1105-1116.
23. Medina, F., M. Ramos, S. Iborra, P. de León, M. Rodríguez-Castro, and M. Del Val. 2009. Furin-processed antigens targeted to the secretory route elicit functional TAP1-/-CD8+ T lymphocytes in vivo. J. Immunol. 183: 4639-4647.
24. Martoglio, B., and B. Dobberstein. 1998. Signal sequences: more than just greasy peptides. Trends Cell Biol. 8: 410-415.
25. Weihofen, A., and B. Martoglio. 2003. Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends Cell Biol. 13: 71-78.
26. Durgeau, A., F. El Hage, I. Vergnon, P. Validire, V. de Montpréville, B. Besse, J. C. Soria, T. van Hall, and F. Mami-Chouaib. 2011. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J. Immunol. 187: 5532-5539.
27. El Hage, F., V. Stroobant, I. Vergnon, J. F. Baurain, H. Echchakir, V. Lazar, S. Chouaib, P. G. Coulie, and F. Mami-Chouaib. 2008. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc. Natl. Acad. Sci. USA 105: 10119-10124.
28. Oliveira, C. C., B. Querido, M. Sluijter, J. Derbinski, S. H. van der Burg, and T. van Hall. 2011. Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires. Eur. J. Immunol. 41: 3114-3124.
29. Verweij, M. C., A. D. Lipińska, D. Koppers-Lalic, E. Quinten, J. Funke, H. C. van Leeuwen, K. Bieńkowska-Szewczyk, J. Koch, M. E. Ressing, and E. J. Wiertz. 2011. Structural and functional analysis of the TAP-inhibiting UL49.5 proteins of varicelloviruses. Mol. Immunol. 48: 2038-2051.
30. van Hall, TSijts, A., M. Camps, R. Offringa, C. Melief, P. M. Kloetzel, and F. Ossendorp. 2000. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J. Exp. Med. 192: 483-494.
31. van Stipdonk, M. J., D. Badia-Martinez, M. Sluijter, R. Offringa, T. van Hall, and A. Achour. 2009. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-Associated epitope gp100. Cancer Res. 69: 7784-7792.
32. Riebeling, C., J. C. Allegood, E. Wang, A. H. Merrill, Jr., and A. H. Futerman. 2003. Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J. Biol. Chem. 278: 43452-43459.
33. Yu, J., S. A. Novgorodov, D. Chudakova, H. Zhu, A. Bielawska, J. Bielawski, L. M. Obeid, M. S. Kindy, and T. I. Gudz. 2007. JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction. J. Biol. Chem. 282: 25940-25949.
34. Golde, T. E., M. S. Wolfe, and D. C. Greenbaum. 2009. Signal peptide peptidases: a family of intramembrane-cleaving proteases that cleave type 2 transmembrane proteins. Semin. Cell Dev. Biol. 20: 225-230.
35. Weihofen, A., M. K. Lemberg, E. Friedmann, H. Rueeger, A. Schmitz, P. Paganetti, G. Rovelli, and B. Martoglio. 2003. Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. J. Biol. Chem. 278: 16528-16533.
36. Weihofen, A., M. K. Lemberg, H. L. Ploegh, M. Bogyo, and B. Martoglio. 2000. Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor. J. Biol. Chem. 275: 30951-30956.
37. Martoglio, B., and T. E. Golde. 2003. Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs. Hum. Mol. Genet. 12(Spec No 2): R201-R206.
38. Friedmann, E., E. Hauben, K. Maylandt, S. Schleeger, S. Vreugde, S. F. Lichtenthaler, P. H. Kuhn, D. Stauffer, G. Rovelli, and B. Martoglio. 2006. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat. Cell Biol. 8: 843-848.
39. Li, X., S. Dang, C. Yan, X. Gong, J. Wang, and Y. Shi. 2013. Structure of a presenilin family intramembrane aspartate protease. Nature 493: 56-61.
40. Fluhrer, R., L. Martin, B. Klier, M. Haug-Kröper, G. Grammer, B. Nuscher, and C. Haass. 2012. The a-helical content of the transmembrane domain of the British dementia protein-2 (Bri2) determines its processing by signal peptide peptidase-like 2b (SPPL2b). J. Biol. Chem. 287: 5156-5163.
41. Lemberg, M. K., and B. Martoglio. 2002. Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis. Mol. Cell 10: 735-744.
42. Lemberg, M. K., and B. Martoglio. 2004. On the mechanism of SPP-catalysed intramembrane proteolysis; conformational control of peptide bond hydrolysis in the plane of the membrane. FEBS Lett. 564: 213-218.
43. McLauchlan, J., M. K. Lemberg, G. Hope, and B. Martoglio. 2002. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J. 21: 3980-3988.
44. Loureiro, J., B. N. Lilley, E. Spooner, V. Noriega, D. Tortorella, and H. L. Ploegh. 2006. Signal peptide peptidase is required for dislocation from the endoplasmic reticulum. Nature 441: 894-897.
45. Schrul, B., K. Kapp, I. Sinning, and B. Dobberstein. 2010. Signal peptide peptidase (SPP) assembles with substrates and misfolded membrane proteins into distinct oligomeric complexes. Biochem. J. 427: 523-534.
46. Snyder, H. L., I. Bacík, J. R. Bennink, G. Kearns, T. W. Behrens, T. Bächi, M. Orlowski, and J. W. Yewdell. 1997. Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing. J. Exp. Med. 186: 1087-1098.
47. Snyder, H. L., I. Bacík, J. W. Yewdell, T. W. Behrens, and J. R. Bennink. 1998. Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. Eur. J. Immunol. 28: 1339-1346.
48. Puente, X. S., L. M. Sánchez, C. M. Overall, and C. López-Otín. 2003. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4: 544-558.
49. Kirkin, V., N. Cahuzac, F. Guardiola-Serrano, S. Huault, K. Lückerath, E. Friedmann, N. Novac,W. S.Wels, B. Martoglio, A. O. Hueber, and M. Zörnig. 2007. The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. Cell Death Differ. 14: 1678-1687.
50. Beisner, D. R., P. Langerak, A. E. Parker, C. Dahlberg, F. J. Otero, S. E. Sutton, L. Poirot, W. Barnes, M. A. Young, S. Niessen, et al. 2013. The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain. J. Exp. Med. 210: 23-30.
51. Bergmann, H., M. Yabas, A. Short, L. Miosge, N. Barthel, C. E. Teh, C. M. Roots, K. R. Bull, Y. Jeelall, K. Horikawa, et al. 2013. B cell survival, surface BCR and BAFFR expression, CD74 metabolism, and CD8-dendritic cells require the intramembrane endopeptidase SPPL2A. J. Exp. Med. 210: 31-40.
52. Schneppenheim, J., R. Dressel, S. Hüttl, R. Lüllmann-Rauch, M. Engelke, K. Dittmann, J. Wienands, E. L. Eskelinen, I. Hermans-Borgmeyer, R. Fluhrer, et al. 2013. The intramembrane protease SPPL2a promotes B cell development and controls endosomal traffic by cleavage of the invariant chain. J. Exp. Med. 210: 41-58.